BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30372726)

  • 1. Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
    Armstrong P; Woody MM; Reichenberg JS; Gavino AC
    Cutis; 2018 Sep; 102(3):E12-E14. PubMed ID: 30372726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
    Puglisi F; Bisagni G; Ciccarese M; Fontanella C; Gamucci T; Leo L; Molino A; Silva RR; Marchetti P
    Future Oncol; 2016 Nov; 12(22):2589-2602. PubMed ID: 27443691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
    Rodriguez CA; Martin T; Lozano R; Gomez A; Cruz JJ
    Breast J; 2017 Nov; 23(6):745-746. PubMed ID: 28845572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A Case of Drug-Induced Lung Injury Associated with Paclitaxel plus Bevacizumab Therapy].
    Yamaguchi Y; Tada Y; Takaya S; Iwamoto A; Yamashiro Y; Shibata S; Ishiguro M; Nishidoi H
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):781-4. PubMed ID: 27306821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    Miller K; Wang M; Gralow J; Dickler M; Cobleigh M; Perez EA; Shenkier T; Cella D; Davidson NE
    N Engl J Med; 2007 Dec; 357(26):2666-76. PubMed ID: 18160686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case.
    Kijima Y; Yoshinaka H; Hirata M; Nakajo A; Arima H; Shinden Y; Ijichi T; Eguchi Y; Okumura H; Uenosono Y; Kurahara H; Ishigami S; Natsugoe S
    Surg Today; 2015 Apr; 45(4):498-502. PubMed ID: 24831658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Liver Atrophy and Failure Associated with Paclitaxel and Bevacizumab Combination Therapy for Metastatic Breast Cancer].
    Yamamoto M; Ikeda M; Kubo S; Tsukioki T; Nakamoto S
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):869-73. PubMed ID: 27431631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
    Nakatsukasa K; Ouchi Y; Sakaguchi K; Goto M; Konishi E; Taguchi T
    Anticancer Res; 2018 Sep; 38(9):5459-5463. PubMed ID: 30194203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folliculotropic Cutaneous Metastases and Lymphangitis Carcinomatosa: When Cutaneous Metastases of Breast Carcinoma Are Mistaken for Cutaneous Infections.
    Paolino G; Panetta C; Didona D; Donati M; Donati P
    Acta Dermatovenerol Croat; 2016 Jun; 24(2):154-7. PubMed ID: 27477179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
    Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y
    J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of Locally Advanced and Metastatic Breast Cancer Treated with Preoperative Bevacizumab Combination Chemotherapy That Attained Local Control].
    Watanabe N; Furukawa J; Minoji T; Tamai K; Kitahara T; Yamamura N; Okamura S; Fukuchi N; Ebisui C; Yokouchi H; Kinuta M
    Gan To Kagaku Ryoho; 2018 Jul; 45(7):1097-1099. PubMed ID: 30042280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
    Mychaluk J; Piprot C; Sevestre H; Merviel P; Gondry J; Fauvet R
    Presse Med; 2009 Sep; 38(9):1370-4. PubMed ID: 19349140
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab: new indication. Metastatic breast cancer: many adverse effects.
    Prescrire Int; 2008 Dec; 17(98):236. PubMed ID: 19422148
    [No Abstract]   [Full Text] [Related]  

  • 15. [Nasal septum perforation and bevacizumab].
    Bengrine-Lefevre L; Afchain P; Chibaudel B; Gervais H; Tournigand C; De Gramont A; Louvet C
    Rev Med Interne; 2011 Apr; 32(4):e43-5. PubMed ID: 21470582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Case of Pseudopancreatic Cyst Development during Bevacizumab plus Paclitaxel Therapy for Pancreatic Metastasis of Breast Cancer].
    Shiina N; Fujisaki K; Miyoshi T; Yokomizo J; Sai G; Wakabayashi Y; Ootsubo Y
    Gan To Kagaku Ryoho; 2021 Aug; 48(8):1061-1063. PubMed ID: 34404077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Case of Axillary Arterial Bleeding after Axillary Metastatic Lymph Node Necrosis during Treatment with Paclitaxel and Bevacizumabfor Breast Cancer].
    Abe N; Ohtake T; Abe S; Aoto K; Okano M; Tachibana K; Yoshida S; Yasuda M; Kimijima I; Takenoshita S
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2062-2064. PubMed ID: 28133222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature.
    Nakamura F; Seino M; Suzuki Y; Sakaki H; Sudo T; Ohta T; Tsutsumi S; Nagase S
    J Med Case Rep; 2019 Nov; 13(1):328. PubMed ID: 31699140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term complete response to carboplatin plus paclitaxel combined with bevacizumab in a patient with metastatic spindle cell carcinoma.
    Sakata S; Saeki S; Sato R; Ishizuka S; Sasaki J; Fujii K
    Respir Investig; 2017 Nov; 55(6):372-375. PubMed ID: 29153418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.